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Abstract
Objective: This study was carried out to determine relative survival rates and trends in outcomes in
patients who underwent resection of periampullary adenocarcinomas (PACs) with curative intent at a
single institution over the last three decades.
Methods: From 1980 to 2011, 2564 pancreaticoduodenectomies (PDs) were performed for PACs.
Pathological diagnosis, therapy and survival were retrospectively analysed.
Results: The primary sites included the pancreas (66%), ampulla (16%), bile duct (12%) and duodenum
(6%). Operation volume increased from 11 per year in the 1980s to 135 per year in the 2000s (P < 0.001).
Patients in the 1980s were younger (median age: 64 years; range: 33–90 years) than those in the 1990s
(median age: 68 years; range: 31–103 years) and 2000s (median age: 68 years; range: 24–93 years) (P <
0.001). Over time, the frequency of a diagnosis of pancreatic cancer arising from intraductal papillary
mucinous neoplasm increased from 2% in the 1980s to 8% in the 2000s (P < 0.001). The rate of 30-day
mortality after surgery in the 1980s was 2%, which was similar to rates in the 1990s (1%) and 2000s (1%).
Survival in each type of PAC did not change over time. Pancreatic cancer was associated with the worst
survival (median survival: 19 months) compared with adenocarcinomas of the ampulla (median survival:
47 months), bile duct (median survival: 23 months) and duodenum (median survival: 54 months)
(P < 0.001).
Conclusions: There are significant differences among PACs in longterm survival following PD. Although
the numbers of patients undergoing safe resection have increased, overall longterm outcomes have not
improved significantly.
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Introduction
Periampullary adenocarcinomas (PACs) are biologically distinct
neoplasms that arise in the epithelia of the pancreatic duct, distal
bile duct, ampulla or duodenum.1 Despite their similar histologi-
cal appearance and close proximity in tissue of origin, longterm
survival following resection of each of the different PACs varies
greatly.2 Pancreatic adenocarcinoma is the most common of all
periampullary cancers, accounting for approximately 44 000 new
patients each year in the USA, followed by ampullary cancer, distal
cholangiocarcinoma and duodenal cancer.3–9 Many patients with
periampullary cancers are found to have locally advanced or
metastatic disease at diagnosis that precludes surgical resection
and are thus unlikely to be curable. In patients with localized
periampullary cancer, pancreaticoduodenectomy (PD) is the only
treatment modality to offer a chance for cure.10,11 Historically,
5-year estimated survival in patients undergoing resection of peri-
ampullary cancers has been poor and ranges from approximately
20% in pancreatic adenocarcinoma to 50% in duodenal
adenocarcinoma.2
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Although studies have reported outcomes for the individual
PACs,2,12–14 relative outcomes in patients undergoing resection for
PACs during the contemporary period are not well characterized.
Moreover, recent trends in survival and outcomes following resec-
tion of PACs over time have not been well documented. Over the
past three decades, numerous studies have reported improve-
ments in operative mortality,5,13,15 preoperative staging and selec-
tion, and adjuvant therapy16–18 for periampullary cancers. With
these presumed advances, the hypothesis of this study was that
outcomes in patients undergoing potentially curative resections of
periampullary cancers might have improved since the 1980s.
The purpose of this study was to determine relative survival and
trends in outcome using a large cohort of patients who underwent
resection of a PAC with curative intent at a single institution over
the last three decades.
Materials and methods
Inclusion criteria and data collection
All patients undergoing PD for a PAC between 1980 and 2011 at
the Johns Hopkins Hospital were identified from a prospectively
maintained database. Periampullary adenocarcinomas were
defined as adenocarcinomas originating in the epithelia of the
ampulla of Vater, distal bile duct (distal cholangiocarcinoma), the
proximal–mid-duodenum, or the head of pancreas. All histologi-
cal variants of pancreatic adenocarcinoma such as tubular, intra-
ductal papillary mucinous neoplasm (IPMN)-associated colloid
and IPMN-associated tubular adenocarcinoma were included.
Patients undergoing resection of other pancreatic neoplasms, such
as neuroendocrine tumours, were excluded from this analysis.
Patient demographics, tumour pathological staging, surgical
treatment-related variables and follow-up data were retrieved
from a prospectively maintained database. Survival data were also
confirmed from the social security death index.
Patient factors evaluated included age and gender. Treatment
factors included the type of operation, necessity for blood vessel
reconstruction, and complications. Postoperative pancreatic
fistula (POPF) was defined according to the International Study
Group on Pancreatic Fistula (ISGPF) definition.19 In brief, drain
amylase was checked when the patient was on regular diet. Post-
operative PF was diagnosed when drain amylase was three times
higher than the upper limit of normal serum at any volume on or
after postoperative day 3. Delayed gastric emptying (DGE) was
defined as an inability to return to standard diet by the end of the
first postoperative week following PD or the reinsertion of a
nasogastric tube prior to this period.20 Ninety-day mortality was
defined as death within 90 days of surgery.
Pathological factors evaluated included location of tumour,
tumour–node–metastasis (TNM) stage, margin status, and histo-
logical differentiation (good, moderate, poor). The primary
pathological diagnosis and the extent of disease were determined
using the standard approach as detailed previously.21 In brief, the
location of the tumour was determined grossly and microscopi-
cally. All four periampullary components were evaluated for in
situ carcinoma. Margins assessed included the pancreatic neck
resection margin, biliary margin, bowel margins and uncinate
margin. Maximal tumour size was determined and defined as the
maximum diameter at pathological examination. The lymph node
ratio (LNR) was defined as the number of nodes involved divided
by the number of lymph nodes examined. Microvascular invasion
was defined as microscopic tumour invasion identified in the
microvascular structure of the surrounding normal tissue, which
was contiguous to the tumour.
For the trend analysis, the cohort was divided into three groups
by decade (1980–1989, 1990–1999 and 2000–2011).
The study was approved by the institutional internal review
board.
Statistical analysis
spss Version 16.0 (SPSS, Inc., Chicago, IL, USA) was used to
analyse and calculate data. Survival curves were estimated using
the Kaplan–Meier method and compared using the Breslow
test. The interquartile range (IQR) is equal to the difference
between the upper and lower quartiles. Continuous variables were
expressed as medians and ranges and compared using the Mann–
Whitney test. Categorical variables were compared using a chi-
squared test (or Fisher’s exact test). Overall survival (OS) was
computed from the time of operative resection to the date of last
follow-up. A P-value of <0.05 was considered to indicate statistical
significance.
Multivariate analysis was undertaken using variables from uni-
variate analysis most likely to impact survival (i.e. P < 0.05) using
the Cox proportional hazards method. For this multivariate analy-
sis, death within 30 days of the operation was excluded to allow
the Cox regression model to accurately identify predictors of sur-
vival related to the malignancy.
Results
Comparisons and trends in patient and
operative characteristics
Between 1980 and 2011, 2564 PDs were performed for PACs at the
Johns Hopkins Hospital. These included 1688 adenocarcinomas
of the head of the pancreas (66%), 401 of the ampulla of Vater
(16%), 317 of the distal common bile duct (12%), and 158 of the
duodenum (6%). Patient demographic data are shown in Table 1.
The median age of the entire cohort was 67 years (range: 24–103
years) and 55% were male. Distal bile duct adenocarcinomas
occurred significantly more often in male (62%) than in female
patients (P = 0.006).
Patients in the 1980s were younger (median age: 64 years; range:
33–90 years) than those in the 1990s (median age: 68 years;
range: 31–103 years) (P < 0.001) and 2000s (median age: 68 years;
range: 24–93 years) (P < 0.001). Over time, the frequency of PD
for pancreatic adenocarcinoma arising from IPMN increased
from 2% (two patients) in the 1980s to 6% (101 patients) in the
2000s (P < 0.001).
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With the growth in the volume of PDs (Fig. 1), surgical com-
plexity also increased. The increase in venous resection and recon-
struction was related to the increase in the number of patients
undergoing resection of pancreatic adenocarcinoma rather than
other periampullary cancers (P < 0.01) (Table 2).
Comparisons and trends in operative complications
The overall complication rate in the entire cohort was 52%. The
most common complications included DGE (16%), POPF (9%)
and wound-related complications (12%). Relative frequencies of
complications differed among the various PACs (Table 3).
Despite differences in complication rates among the PACs, each
cohort had similar rates of 30-day (P = 0.89) and 90-day (P = 0.47)
mortality. The rate of 30-day mortality after PD in the 1980s was
2% and thus did not differ significantly from the rates of 1%
reported in both the 1990s and 2000s (P = 0.79). The rate of
90-day mortality after PD was 4% in the 1980s, and remained at
that level in the 1990s and 2000s.
Comparisons and trends in pathological data
The median tumour size of all pathological types was 2.5 cm
(range: 0–17 cm) (Table 1) and tumour size was similar in amp-
ullary cancer and bile duct cancer. The median tumour size
in duodenal cancer was larger than that in ampullary and bile
duct cancer (P < 0.001), and larger than that in pancreatic cancer
(P < 0.001).
No difference in the grade of tumour differentiation was iden-
tified among all types of PAC (Table 1). The overall rate of margin
positivity for all tumour types was 21%, with the majority of cases
classified as of R1 status. Margin status is summarized in Table 4.
The rate of margin positivity varied significantly based on type of
PAC. The frequency of positive margin resection did not change
over the years for any of the PACs. Data on lymph node metastasis
status are summarized in Table 5. Patients with pancreatic adeno-
carcinoma were more likely to have regional lymph node metas-
tases (P < 0.001).
Comparisons and trends in survival
The estimated median survival and 5-year OS rate for the entire
cohort were 22 months and 26%, respectively. These values varied
Table 1 Demographic data for patients with periampullary adenocarcinomas (n = 2564)
Ampullary Bile duct Duodenal Pancreatic P-value
(n = 401) (n = 317) (n = 158) (n = 1688)
Age, years, median (range) 68 (29–90) 68 (34–92) 67 (24–103) 67 (31–93) 0.49
Male gender, n (%) 230 (57%) 196 (62%) 87 (55%) 899 (53%) 0.33
Tumour size, cm, median (range) 2.1 (0–6.6) 2.1 (0–7) 3.7 (0.2–13) 3.1 (0–17)
Differentiation, n (%)
Good 18 (4%) 13 (4%) 4 (3%) 68 (4%)
Moderate 218 (54%) 166 (52%) 87 (55%) 898 (53%)
Poor or anaplastic 138 (34%) 149 (47%) 52 (33%) 653 (39%)
Unknown 26 (6%) 19 (6%) 15 (9%) 69 (4%)
Microvascular invasion, n (%) 129 (32%) 93 (29%) 45 (28%) 671 (40%)a <0.001
Perineural invasion, n (%) 124 (31%) 190 (60%) 47 (30%) 1164 (69%)
Lymph node ratio, median 0.07 0.08 0.07 0.14a <0.001
aPatients with pancreatic adenocarcinoma were more likely to have microvascular invasion than patients with other types of periampullary adeno-
carcinoma (P < 0.001). Perineural invasion was also more common in pancreatic adenocarcinoma than in cholangiocarcinoma (P = 0.0016) and
ampullary and duodenal adenocarcinoma (P < 0.001).
1980s
(111 patients)
1990s
(830 patients)
2000s
1980s 1990s 2000s
(1623 patients)
Ampullary (n = 401) 20 (18%) 132 (16%) 249 (15%) 
Bile duct (n = 317) 17 (15%) 141 (17%) 159 (10%) 
Duodenal (n = 158) 8 (7%) 50 (6%) 100 (6%) 
Pancreatic (n = 1688) (59%) 507 (61%) 1115 (69%) 
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Figure 1 Rates of pancreaticoduodenectomy in patients with peri-
ampullary adenocarcinomas during 1980–2011. Case volume
increased progressively during each of the decades (P < 0.001).
Patients undergoing pancreaticoduodenectomy for pancreatic
adenocarcinoma increased significantly not only in number (P <
0.001), but also in proportion (P = 0.003)
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significantly among the various PAC types. Pancreatic adenocar-
cinoma was associated with the worst median OS (19 months)
compared with ampullary adenocarcinoma (47 months), distal
cholangiocarcinoma (23 months) and duodenal adenocarcinoma
(54 months) (Fig. 2). Similarly, estimated 5-year survival was
lowest in pancreatic adenocarcinoma (18%) compared with other
PACs of the ampulla (45%), distal bile duct (27%) and duodenum
(49%) (Fig. 2). Overall survival in each type of PAC did not
change over time (Fig. 3).
In univariate analysis, tumour type, preoperative jaundice,
pain, weight loss, vein resection during surgery, positive margin,
nodal metastasis, and occurrence of POPF were associated with
Table 2 Incidences of major venous resection during pancreaticoduodenectomy (PD) in patients with periampullary adenocarcinomas
Ampulla Distal bile duct Duodenum Head of pancreas Total
(n = 401) (n = 317) (n = 158) (n = 1688) (n = 2564)
1980s (n = 111), n (%) 0 0 1 (2%) 0 1 (1%)
1990s (n = 830), n (%) 0 0 0 15 (3%) 15 (2%)
2000s (n = 1623), n (%) 3 (1%) 8 (5%) 1 (2%) 66 (6%) 78 (5%)
Total 3 (1%) 8 (3%) 2 (1%) 81 (5%)
More vein resections were performed during PD in the 2000s than in the previous two decades (P < 0.001). Pancreaticoduodenectomy in pancreatic
cancer involved more vein resection than PD in ampullary or duodenal cancer. (P < 0.01).
Table 3 Rates of postoperative pancreatic fistula, delayed gastric emptying and wound-related complications in patients undergoing
pancreaticoduodenectomy for periampullary adenocarcinomas during 1980–2011 by disease type and decade
Ampulla
(n = 401)
Distal bile duct
(n = 317)
Duodenum
(n = 158)
Head of pancreas
(n = 1688)
Total
(n = 2564)
Rates of postoperative pancreatic fistula, n (%)
1980s (n = 111) 1 (5%) 2 (12%) 0 0 3 (3%)
1990s (n = 830) 21 (16%) 17 (12%) 5 (10%) 18 (4%) 61 (7%)
2000s (n = 1623) 35 (14%) 22 (14%) 22 (22%) 75 (7%) 154 (9%)
Total 57 (14%) 41 (13%) 27 (17%) 93 (6%) 218 (9%)
Rates of delayed gastric emptying, n (%)
1980s (n = 111) 3 (15%) 1 (6%) 2 (25%) 2 (3%) 8 (7%)
1990s (n = 830) 20 (15%) 20 (14%) 9 (18%) 74 (15%) 123 (15%)
2000s (n = 1623) 46 (18%) 18 (11%) 14 (14%) 190 (17%) 268 (17%)
Total 69 (17%) 39 (12%) 25 (16%) 266 (16%) 399 (16%)
Rates of wound-related complications, n (%)
1980s (n = 111) 4 (20%) 1 (6%) 0 1 (2%) 6 (5%)
1990s (n = 830) 14 (11%) 18 (13%) 5 (10%) 33 (7%) 70 (8%)
2000s (n = 1623) 37 (15%) 26 (16%) 16 (16%) 151 (14%) 230 (14%)
Total 55 (14%) 45 (14%) 21 (13%) 185 (11%) 306 (12%)
Non-pancreatic adenocarcinomas were associated with a significantly higher incidence of postoperative pancreatic fistula (POPF) than pancreatic
adenocarcinoma (P < 0.001). Comparisons by decade showed a higher incidence of POPF in the 2000s than in the 1980s (P < 0.05).
Table 4 Positive margin status in patients undergoing pancreaticoduodenectomy for periampullary adenocarcinomas during 1980–2011 by
disease type
Margin status Ampulla
(n = 401)
Distal bile duct
(n = 317)
Duodenum
(n = 158)
Head of pancreas
(n = 1688)
Total
(n = 2564)
Negative, n (%) 368 (92%) 252 (79%) 134 (85%) 1054 (62%) 1807 (71%)
Tumour within 1 mm, n (%) 12 (3%) 16 (5%) 9 (6%) 185 (11%)a 222 (9%)
Positive, n (%) 13 (3%) 47 (15%) 10 (6%) 440 (26%)a 510 (21%)
Unknown, n (%) 9 (2%) 3 (1%) 5 (3%) 9 (1%) 26 (1%)
aPositive resection margins were significantly higher in pancreatic adenocarcinoma (26%) than in adenocarcinomas of the bile duct (15%), ampulla
(3%) or duodenum (6%) (P < 0.001). Pancreatic adenocarcinoma also had a significantly higher proportion of carcinoma within 1 mm of the margin
compared with the other periampullary adenocarcinomas (P < 0.001).
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worse OS. In a Cox proportional hazards multivariate regression
model, tumour type, vein resection, positive margin and nodal
metastasis were strongly associated with OS. Nodal metastasis had
the strongest association with OS [hazard ratio (HR) 1.61; P <
0.001], whereas vein resection had the weakest association with
OS (HR = 1.25; P = 0.02) (Table 6).
Discussion
The primary goal of this study was to evaluate trends in clinico-
pathological features and outcomes among the various PACs. A
cohort of 2564 patients submitted to resection of PACs was studied.
The study spans a period during which significant management
changes occurred, which allows for a meaningful analysis of trends
in outcomes. This work provides a perspective of changing
experience in the management of PACs at a single institution.
Pancreatic cancer was confirmed to have the most aggressive fea-
tures, including the highest rates of regional lymph node involve-
ment and positive margins, and poorest longterm survival.13 The
best OS was seen in both ampullary and duodenal cancer, both of
which had 5-year survival rates over twice that found in pancreatic
cancer. It should be noted, however, that as a group periampullary
cancers are among the most lethal of gastrointestinal neoplasms.
This study shows a trend towards an increase in the number of
PDs performed at a single institution over the past three decades.
The relative distribution of periampullary cancers subjected to
resection was unchanged over this period. Significant increases
were apparent in the number and proportion of patients under-
going PD for IPMN-associated cancers. Over the three decades,
30-day mortality remained stable at about 1–2%, despite a trend
towards increased age in patients undergoing resection and an
increase in the complexity of the operation as greater numbers of
patients underwent vein resection.
Based on the premise that refinements in staging, systemic
therapy and radiotherapy have been made over the past three
decades, the present study sought to determine if these changes
were associated with improvements in survival over this period.
Unfortunately, no trends that would suggest improved longterm
outcomes over time were identified. A decade-by-decade com-
parison demonstrated no improvement in survival since the
1980s. In particular, in pancreatic cancer, in the setting of which
significant evolution in the provision of adjuvant chemotherapy
and chemoradiotherapy has occurred,22 no trend towards
improved survival was found.
As pancreatic cancer is the most common PAC and studies
often combine the various PACs, there may be a perception that
all of these neoplasms are uniformly associated with a poor prog-
nosis.18,23 The current study demonstrates that periampullary
cancers are associated with significantly different longterm sur-
vival rates. This finding is interesting in light of the fact that these
adenocarcinomas originate in tissues that are separated by only
millimetres, have nearly identical venous and lymphatic drainage
on the gross anatomic level, and are often indistinguishable on
standard histopathological assessment; yet they are associated
with very different outcomes. This work, along with that of
others, confirms that the unique intrinsic characteristics of each
PAC, often described as its ‘biological behaviour’, remain the
most important prognostic indicators in periampullary cancers
amenable to resection.24
Table 5 Positive lymph node metastasis in patients undergoing pancreaticoduodenectomy for periampullary adenocarcinomas during
1980–2011 by disease type and decade
Ampulla
(n = 401)
Distal bile duct
(n = 317)
Duodenum
(n = 158)
Head of pancreas
(n = 1688)
1980s (n = 111) 5 (25%) 5 (29%) 4 (50%) 41 (62%)
1990s (n = 830) 66 (50%) 92 (65%) 31 (62%) 374 (74%)
2000s (n = 1623) 159 (64%) 108 (68%) 66 (66%) 861 (77%)
Total 230 (57%) 205 (65%) 101 (64%) 1275 (76%)
Patients with pancreatic adenocarcinoma were more likely to have regional lymph node metastases (P < 0.001). The rate of lymph node metastasis
increased over the decades in patients with pancreatic adenocarcinoma (62% in the 1980s versus 77% in the 2000s; P = 0.008).
Median, IQR,
months
IQR 95% CI,
months
5-year OS
Ampullary (n = 401) 47–222 16–238 35–59 45%
Bile duct (n = 317) 23–56 11–67 19–27 27%
Duodenal (n = 158) 54–162 17–179 11–97 49%
Pancreatic (n = 1688) 19–32 10–42 18–20 18%
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Figure 2 Overall survival (OS) in patients with periampullary adeno-
carcinomas undergoing pancreaticoduodenectomy during 1980–
2011. IQR, interquartile range; 95% CI, 95% confidence interval
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1980s 1990s 2000s Median follow-
up of survivors, 
months
n
5-year
OS 
Death n n
5-year
OS
Death
5-year
OS
Death 
Ampullary  20 43% 18 132 41% 98 249 49% 134 34
Bile duct  17 42% 15 141 21% 125 159 29% 106 19
Duodenal  8 50% 7 50 49% 36 100 47% 52 41
Pancreac  65 15% 61 507 19% 469 1115 18% 837 18
Number at risk 1980s 1990s 2000s 
Months 50 100 150 200 250 50 100 150 200 250 50 100 150 200 250 
Ampullary 9 6 5 4 2 82 43 32 9 2 96 41
Bile duct 7 6 5 4 2 34 22 17 2 37 11 9
Duodenal 5 5 2 1 1 25 23 16 4 1 37 15 
Pancreac 12 6 4 4 3 108 71 44 8 1 149 46 
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Duodenal Pancreatic 
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Figure 3 Survival analysis by disease type and decade in patients with periampullary adenocarcinomas undergoing pancreaticoduodenec-
tomy during 1980–2011, showing the number of deaths at the end of the study for each time period and median follow-up in survivors of
each tumour type. OS, overall survival
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Similarly to this study, others have shown that OS in duodenal
and ampullary adenocarcinomas is much better than in distal
cholangiocarcinoma and pancreatic cancer. One explanation for
this observation is that duodenal and ampullary adenocarcinomas
are diagnosed at an earlier stage than cholangiocarcinoma or pan-
creatic carcinoma. Indeed, in the current study, more patients
undergoing resection for pancreatic cancer were diagnosed at a
more advanced stage and demonstrated higher rates of positive
lymph nodes compared with patients diagnosed with other types
of PAC (P < 0.001). However, an alternative explanation is that the
lower stage at diagnosis of the non-pancreatic PAC reflects an
inherent lower propensity towards metastasis of these tumours.
Which of these theories is correct cannot be concluded from the
current data. However, the suggestion that the unique biology of
each PAC has a role to play is supported by recent reports that have
shed light on the genetic underpinnings of these tumours.25–29
Histology and genetic association have suggested that ampullary
cancer is closer to intestinal cancer than to pancreatobiliary can-
cer.30,31 The pancreatobiliary type of differentiation independently
predicts a poor prognosis after PD in PACs.32,33
Several published studies have evaluated predictors of out-
comes in periampullary cancers after resection. Positive lymph
node status and LNR were associated with worse survival rates
among those with no evidence of distant metastatic disease.24,34
Perineural growth and angioinvasion were also shown to be
important risk factors for survival in periampullary cancers after
resection.35 These studies were restricted by relatively small
numbers of patients, which prohibited robust multivariate analy-
sis. Data derived from the Surveillance, Epidemiology and End
Results (SEER) database have been used to achieve sufficient sta-
tistical power. However, these data lack detail on the characteris-
tics of the treatment regimen. In this study, multivariate analysis
in a relatively large population of patients linked to detailed data
showed tumour type, vein resection rate, margin status and nodal
status to be associated with worse OS in PACs.
The limitations of this study include: (i) its status as a retro-
spective analysis, which has the potential to be influenced by selec-
tion bias; (ii) relatively few patients were operated during the
1980s in comparison with the more recent decades; (iii) the study
includes no data on the actual rate and composition of neoadju-
vant and adjuvant chemoradiation therapy, and (iv) the fact that
no data on disease-specific survival were available.
Conclusions
Despite a presumed improvement in disease staging and the pro-
vision of adjunct therapies over time, there has been no measur-
able improvement in longterm survival in any of the PACs.
Periampullary adenocarcinomas are associated with distinct out-
comes. The best OS was seen in both ampullary and duodenal
cancer and the worst in pancreatic cancer.
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